Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Identification and Estimation of Undetected COVID-19 Cases Using Testing Data from Iceland

Karl M. Aspelund, Michael Droste, James H. Stock, Christopher D. Walker
doi: https://doi.org/10.1101/2020.04.06.20055582
Karl M. Aspelund
†MIT. Email:
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kmasp@mit.edu
Michael Droste
‡Harvard University. Email:
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mdroste@fas.harvard.edu
James H. Stock
§Harvard University. Email:
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: james_stock@harvard.edu
Christopher D. Walker
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: cwalker@g.harvard.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

In the early stages of the COVID-19 pandemic, international testing efforts tended to target individuals whose symptoms and/or jobs placed them at a high presumed risk of infection. Testing regimes of this sort potentially result in a high proportion of cases going undetected. Quantifying this parameter, which we refer to as the undetected rate, is an important contribution to the analysis of the spread of the SARS-CoV-2 virus. We show that partial identification techniques can credibly deal with the data problems that common COVID-19 testing programs induce (i.e. excluding quarantined individuals from testing and low participation in random screening programs). We use public data from two Icelandic testing regimes during the first month of the outbreak and estimate an identified interval for the undetected rate. Our main approach estimates that the undetected rate was between 89% and 93% before the medical system broadened its eligibility criteria and between 80% and 90% after.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

We have no external support for this project. This material is based upon work supported by the National Science Foundation Graduate Research Fellowship under Grant No. 1122374.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • * This article was previously circulated as “Estimates of the Undetected Rate among the SARS-CoV-2 Infected using Testing Data from Iceland.”

  • ↵14 https://px.hagstofa.is/pxen/pxweb/en/Ibuar/Ibuarmannfjoldi1_yfirlityfirlit_mannfjolda/MAN00000.px/table/tableViewLayout1/?rxid=cdf68733-56cd-41c8-8801-d73ca7ded1cd

  • ↵15 In Icelandic: https://www.landlaeknir.is/servlet/file/store93/item32967/influensulik.einkenni.uppfaersla.a.vef.okt2017.AG.xls_%C3%A1n%20myndar%20og%20aldursdreifingu.xls

  • ↵16 March 20, in Icelandic: https://www.almannavarnir.is/utgefid-efni/stoduskyrsla-koronaveira-covid-19-20032020/?wpdmdl=24791

    April 1, in Icelandic:

    https://www.almannavarnir.is/utgefid-efni/stoduskyrsla-koronaveira-02032020-2/?wpdmdl=24580

Data Availability

All data are publicly available. We use counts of tests and confirmed COVID-19 infections from the Icelandic Health Directorate's COVID-19 information website. We also use counts of cases reporting flu-like symptoms from the influenza website of the country's Health Directorate. We use quarantine numbers from the Department of Civil Defense's announcement page.

https://www.landlaeknir.is/servlet/file/store93/item32967/influensulik.einkenni.uppfaersla.a.vef.okt2017.AG.xls_%C3%A1n%20myndar%20og%20aldursdreifingu.xls

https://www.covid.is/data

https://www.almannavarnir.is/utgefid-efni/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted June 23, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Identification and Estimation of Undetected COVID-19 Cases Using Testing Data from Iceland
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Identification and Estimation of Undetected COVID-19 Cases Using Testing Data from Iceland
Karl M. Aspelund, Michael Droste, James H. Stock, Christopher D. Walker
medRxiv 2020.04.06.20055582; doi: https://doi.org/10.1101/2020.04.06.20055582
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Identification and Estimation of Undetected COVID-19 Cases Using Testing Data from Iceland
Karl M. Aspelund, Michael Droste, James H. Stock, Christopher D. Walker
medRxiv 2020.04.06.20055582; doi: https://doi.org/10.1101/2020.04.06.20055582

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (506)
  • Anesthesia (110)
  • Cardiovascular Medicine (1244)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (532)
  • Epidemiology (10027)
  • Forensic Medicine (5)
  • Gastroenterology (500)
  • Genetic and Genomic Medicine (2462)
  • Geriatric Medicine (238)
  • Health Economics (479)
  • Health Informatics (1645)
  • Health Policy (753)
  • Health Systems and Quality Improvement (636)
  • Hematology (250)
  • HIV/AIDS (535)
  • Infectious Diseases (except HIV/AIDS) (11871)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (253)
  • Medical Ethics (75)
  • Nephrology (268)
  • Neurology (2289)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (537)
  • Oncology (1248)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (325)
  • Pediatrics (733)
  • Pharmacology and Therapeutics (314)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2281)
  • Public and Global Health (4840)
  • Radiology and Imaging (838)
  • Rehabilitation Medicine and Physical Therapy (492)
  • Respiratory Medicine (651)
  • Rheumatology (286)
  • Sexual and Reproductive Health (240)
  • Sports Medicine (227)
  • Surgery (268)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)